HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Presenilin-1

Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PEPTIDES precursors. PSEN1 mutations cause early-onset ALZHEIMER DISEASE type 3 that may occur as early as 30 years of age in humans.
Also Known As:
Presenilin 1; S182 Protein
Networked: 1059 relevant articles (6 outcomes, 86 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lopera, Francisco: 20 articles (03/2015 - 05/2003)
2. Sisodia, Sangram S: 10 articles (03/2014 - 07/2004)
3. Fraser, P E: 8 articles (05/2015 - 05/2000)
4. Schofield, Peter R: 8 articles (01/2015 - 04/2002)
5. Larner, A J: 8 articles (01/2013 - 05/2003)
6. Elder, Gregory A: 8 articles (01/2012 - 06/2002)
7. Halliday, Glenda M: 8 articles (05/2010 - 04/2002)
8. Mattson, Mark P: 8 articles (01/2010 - 05/2002)
9. Cruts, M: 8 articles (08/2004 - 02/2000)
10. Reiman, Eric M: 7 articles (03/2015 - 12/2012)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
01/01/2011 - "Comparison of presenilin 1 and sporadic Alzheimer's disease groups revealed significantly greater thalamic retention in the presenilin 1 group and significantly greater frontotemporal retention in the sporadic Alzheimer's disease group. "
11/01/2015 - "A Study On Cytogenetic And Molecular Analysis Of Presenilin 1 (Ps1) Gene In Alzheimer's Disease."
01/01/2015 - "A large, genetically-isolated community in Antioquia, Colombia, with early-onset familial Alzheimer's disease due to a presenilin-1 mutation is ideally suited for the study of molecular mechanisms of AD, and hence accelerate the discovery of new or alternative treatment approaches. "
06/01/2014 - "We capitalized on longitudinal data collected from 1995 to 2010 from cognitively unimpaired presenilin 1 (PSEN1) E280A mutation carriers from the world's largest known early-onset autosomal dominant Alzheimer's disease kindred to identify a composite cognitive test with the greatest statistical power to track preclinical Alzheimer's disease decline and estimate the number of carriers age 30 years and older needed to detect a treatment effect in the Alzheimer's Prevention Initiative's (API) preclinical Alzheimer's disease treatment trial. "
07/01/2011 - "In a recent study, we provide evidence that specific transcript variants (TVs) of ubiquilin-1, which are genetically and functionally associated to Alzheimer's disease (AD), regulate proteasomal and aggresomal targeting of presenilin-1 (PS1), a key player in AD pathogenesis. "
2. Amyloidosis
3. Memory Disorders (Memory Loss)
4. Cholangiocarcinoma
5. Neuroblastoma

Related Drugs and Biologics

1. Amyloid (Amyloid Fibrils)
2. Presenilin-2
3. Amyloid Precursor Protein Secretases (beta-Secretase)
4. ferulic acid (sodium ferulate)
5. Endocannabinoids (Endocannabinoid)
6. Apolipoprotein A-I (Apolipoprotein A1)
7. Flavin-Adenine Dinucleotide (FAD)
8. Presenilins
9. Proteins (Proteins, Gene)
10. Amyloid beta-Peptides

Related Therapies and Procedures

1. Transplantation (Transplant Recipients)
2. Drug Therapy (Chemotherapy)
3. Heterologous Transplantation (Xenotransplantation)
4. Ovariectomy (Oophorectomy)
5. Immunotherapy